3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Sezary Syndrome
2
Mycosis Fungoides
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hodgkin Disease
1
Hepatitis
1
Hematologic Neoplasms
1
Colitis
1
Burkitt Lymphoma
1
Anemia, Refractory, with Excess of Blasts
1
Anemia, Refractory
1
Interventions
Mycophenolic Acid
2
vedolizumab
1
Ursodeoxycholic Acid
1
Steroids
1
Sofosbuvir
1
Ribavirin
1
Prednisone
1
Photopheresis
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Methoxsalen
1
Infliximab
1
Azathioprine
1
Adrenal Cortex Hormones
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hepatitis
×
Photopheresis
×
Clear all
NCT07619898
2026-06-02
PHOENIX-ECP
Therakos LLC
Phase 2
Not yet recruiting
112 enrolled